Glucocerebrosidase gene-deficient mouse recapitulates gaucher disease displaying cellular and molecular dysregulation beyond the macrophage

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 45, 2010, Pages 19473-19478

  Mistrya, Pramod K ^a,b   Liua, Jun ^a   Yanga, Mei ^a   Nottolic, Timothy ^c   McGratha, James ^a,d   Jaine, Dhanpat ^e   Zhangf, Kate ^f   Keutzerf, Joan ^f   Chuangf, Wei Lein ^f   Mehalb, Wajahat Z ^b   Zhaog, Hongyu ^g   Lin, Aiping ^g   Maneh, Shrikant ^e   Liu, Xuan ^h   Peng, Yuan Z ^h   Li, Jian H ^h   Agrawal, Manasi ^h   Zhu, Ling Ling ^h   Blair, Harry C ⁱ   Robinson, Lisa J ⁱ   Iqbal, Jameel ^h   Sun, Li ^h   Zaidi, Mone ^h   more..

^a Departments of Pediatrics   (United States)

^b Medicine   (United States)

^c Comparative Medicine ^*  (United States)

^d Genetics   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Genzyme   (United States)

^g YALE UNIVERSITY   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Glucosylsphingosine; Osteoblast; Osteopenia; PKC; T cells

Indexed keywords

GAMMA INTERFERON; GLUCOSYLCERAMIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DENDRITIC CELL; GAUCHER DISEASE; GENE DELETION; HEMATOPOIETIC CELL; IMMUNOPHENOTYPING; MACROPHAGE; MESENCHYME CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE; THYMUS;

EID: 78650614891     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1003308107     Document Type: Article

References (26)

1. Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372:1263-1271.
2. Sidransky E (2004) Gaucher disease: Complexity in a "simple" disorder. Mol Genet Metab 83:6-15.
3. Cox TM (2001) Gaucher disease: Understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 24(Suppl 2):106-121.
4. Taddei TH, et al. (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84:208-214.
5. Mistry PK, et al. (2002) Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77:91-98.
6. Taddei T, et al. (2010) High incidence of cholesterol gallstones in Gaucher disease: Characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis 33:291-300.
7. Sidransky E (2005) Gaucher disease and parkinsonism. Mol Genet Metab 84:302-304.
8. Elstein D, Itzchaki M, Mankin HJ (1997) Skeletal involvement in Gaucher's disease. Baillieres Clin Haematol 10:793-816.
9. Sims KB, et al. (2008) Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: Results of a 48-month longitudinal cohort study. Clin Genet 73:430-440.
10. Wenstrup RJ, et al. (2004) Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104:1253-1257.
11. Sidransky E, Ginns EI (1997) Gaucher's disease: The best laid schemes of mice and men. Baillieres Clin Haematol 10:725-737.
12. Xu YH, Quinn B, Witte D, Grabowski GA (2003) Viable mouse models of acid betaglucosidase deficiency: The defect in Gaucher disease. Am J Pathol 163:2093-2101.
13. Mizukami H, et al. (2002) Systemic inflammation in glucocerebrosidase- deficient mice with minimal glucosylceramide storage. J Clin Invest 109:1215-1221.
14. Enquist IB, et al. (2006) Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA 103:13819-13824.
15. Kühn R, Schwenk F, Aguet M, Rajewsky K (1995) Inducible gene targeting in mice. Science 269:1427-1429.
16. Aerts JM, et al. (2008) Biomarkers for lysosomal storage disorders: Identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr Suppl 97:7-14.
17. Elleder M (2006) Glucosylceramide transfer from lysosomes-the missing link in molecular pathology of glucosylceramidase deficiency: A hypothesis based on existing data. J Inherit Metab Dis 29:707-715.
18. Campeau PM, et al. (2009) Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 114: 3181-3190.
19. Ryu J, et al. (2006) Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J 25:5840-5851.
20. Ginzburg L, Kacher Y, Futerman AH (2004) The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 15:417-431.
21. Lukina E, et al. (2010) A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116:893-899.
22. Pastores GM, Elstein D, Hrebícek M, Zimran A (2007) Effect of miglustat on bone disease in adults with type 1 Gaucher disease: A pooled analysis of three multinational, openlabel studies. Clin Ther 29:1645-1654.
23. Hannun YA, Bell RM (1989) Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 243:500-507.
24. Shayman JA, et al. (1991) Modulation of renal epithelial cell growth by glucosylceramide. Association with protein kinase C, sphingosine, and diacylglycerol. J Biol Chem 266: 22968-22974.
25. Im DS, Heise CE, Nguyen T, O'Dowd BF, Lynch KR (2001) Identification of a molecular target of psychosine and its role in globoid cell formation. J Cell Biol 153:429-434.
26. Sun L, et al. (2006) FSH directly regulates bone mass. Cell 125:247-260.